辅助化疗与局部浸润性淋巴结阴性非小细胞肺癌生存改善相关
该研究基于美国国家癌症数据库,纳入1998至2010年间824例接受肺及胸壁联合切除的pT3N0非小细胞肺癌患者,其中255例(31%)接受辅助化疗。多变量分析显示辅助化疗与生存改善相关(HR 0.74,95%CI 0.6-0.9),年轻和住院时间短与接受辅助化疗的可能性更高相关。
要点
- pT3N0非小细胞肺癌行肺及胸壁切除后,辅助化疗与生存改善独立相关。
- 辅助化疗组患者更年轻且住院时间更短,但合并症、肿瘤大小等两组相似。
- 即使无淋巴结转移,局部晚期患者也应强烈考虑术后辅助化疗。
核心结论
- 对于接受肺叶切除联合胸壁切除的局部晚期淋巴结阴性非小细胞肺癌患者,辅助化疗与改善生存相关(HR 0.74,95%CI 0.6-0.9)。
研究设计与样本
- 回顾性队列研究,数据来自美国国家癌症数据库,纳入1998至2010年间824例接受肺及胸壁联合切除的pT3N0非小细胞肺癌患者。
主要发现
- 255例(31%)患者接受辅助化疗。
- 辅助化疗组患者更年轻且住院时间更短。
- 两组合并症、肿瘤大小、非计划再入院率和不完全切除率相似。
- 多变量分析中,年轻和住院时间短与接受辅助化疗的可能性更高相关。
- 辅助化疗与改善生存相关(HR 0.74,95%CI 0.6-0.9),而年龄增加、白人种族、住院时间、肿瘤大小和残留肿瘤与死亡风险增加独立相关。
临床怎么用
- 对于局部晚期淋巴结阴性非小细胞肺癌行肺叶切除联合胸壁切除的患者,应强烈考虑术后辅助化疗。
- 辅助化疗的实际选择受围手术期因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objectives of this study are to explore factors that are associated with use of adjuvant chemotherapy and to evaluate its impact on overall survival in node-negative patients who undergo lung and chest wall resection for non-small cell lung cancer (NSCLC). METHODS: Patients who underwent concomitant lung and chest wall resection for NSCLC were abstracted from the National Cancer Database. Clinical, pathologic, treatment, and follow-up data were obtained. Patients with pathologic nodal metastases or patients who received any radiation treatment were excluded, and the cohort was dichotomized based on administration of adjuvant postoperative chemotherapy. RESULTS: Between 1998 and 2010, 824 patients met the inclusion criteria. This cohort exclusively consisted of pT3 N0 patients who did not receive any induction treatment or adjuvant radiation treatment. Adjuvant chemotherapy was administered to 255 patients (31%). Patients in the chemotherapy group were younger and had shorter inpatient length of stay. Both groups had similar comorbidities, tumor size, unplanned readmission rate, and incomplete resection rate. In multivariable analysis, younger age and shorter length of stay were associated with a greater likelihood of receiving adjuvant chemotherapy. Adjuvant chemotherapy was associated with improved survival (hazard ratio 0.74, 95% CI: 0.6 to 0.9), whereas increasing age, white race, length of inpatient stay, tumor size, and residual tumor were independently associated with greater risk of death. CONCLUSIONS: Patients who undergo lobectomy with chest wall resection for locally advanced NSCLC should be strongly considered for postoperative adjuvant chemotherapy even in the absence of nodal disease. Actual selection of patients for adjuvant chemotherapy is affected by perioperative factors.
引用
- Ahmad U, Crabtree TD, Patel AP, et al. Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer. Ann Thorac Surg. 2017. PMID: 28433225. doi:10.1016/j.athoracsur.2017.01.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。